Hepcidin Levels in Preterm Infants

Completed

• Conditions: Anemia of Prematurity; Preterm Infants; Neonatal Sepsis

• Registration Number: NCT01539356
• Lead Sponsor: Meir Medical Center

Brief Summary

A recently isolated peptide hormone, hepcidin, is thought to be the principal regulator of iron homeostasis. Hepcidin acts by limiting intestinal iron absorption and promoting iron retention in reticuloendothelial cells. The aims of this study were to determine serum hepcidin levels in preterm infants who receive blood transfusion and preterm infants having sepsis, in order to assess possible relationships between hepcidin and serum iron, serum ferritin,in iron load situations.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-02-21
• Study First Submitted QC: 2012-02-24
• Study First Posted: 2012-02-27
• Study Start: 2012-03
• Status Verified: 2012-11
• Primary Completion: 2013-02
• Study Completion: 2013-08
• Last Update Submitted: 2016-03-15
• Last Update Posted: 2016-03-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

• Preterm < 38 weeks gestation
• Need of blood test for anemia or suspected sepsis

Exclusion Criteria

• Major congenital anomalies
• Birth Asphyxia

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Increase in Hepcidin levels by 30%	within 24-72 h

Trial Locations

Locations (1)

Neonatal Intensive Care Unit; 🇮🇱 Kfar-Saba, Israel